<DOC>
	<DOCNO>NCT03018015</DOCNO>
	<brief_summary>The present study conduct order ass bioequivalence Test product ( Ibuprofen 400 mg oral powder ) Reference product 1 ( Brufen 400 mg film-coated tablet ) , approve market product European Union . Testing bioequivalence perform consider AUC0-tlast Cmax obtain oral single dose fast administration ibuprofen . In addition conventional immediate release tablet use Reference 1 , soft capsule formulation apply Reference 2 ( Spalt Forte 400 mg Weichkapseln ) , example product fast absorption rate . All 3 immediate release preparation contain 400 mg ibuprofen .</brief_summary>
	<brief_title>Ibuprofen Bioavailability Trial With Oral Single Dose Administration .</brief_title>
	<detailed_description>The clinical trial perform single centre , open-label , randomise ( order treatment ) , balance , 3-period , 6-sequence , single dose change-over design administration fast condition separate washout period least 2 treatment-free day . Blood sample collection perform 16 h administration . This time consider adequate characterise plasma concentration vs. time profile long enough reliable estimation extent absorption , i.e . AUC derive measurement expect cover least 80 % AUC extrapolate infinity .</detailed_description>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>1. sex : male/female 2. ethnic origin : Caucasian 3. age : 18 year old 4. bodymass index ( BMI ) : ≥ 18.5 kg/m² ≤ 30.0 kg/m² , body weight &gt; 40 kg 5. good state health 6. nonsmoker exsmoker least 3 month 7. write informed consent , inform benefit potential risk clinical trial , well detail insurance take cover subject participate clinical trial 1. exist cardiac and/or haematological disease pathological finding , might interfere safety tolerability active ingredient 2. exist hepatic and/or renal disease pathological finding , might interfere safety tolerability , and/or pharmacokinetics active ingredient 3. exist gastrointestinal disease pathological finding , might interfere safety , tolerability , absorption and/or pharmacokinetics active ingredient 4. history gastrointestinal bleeding perforation , relate previous NSAID therapy 5. existing , history , recurrent gastrointestinal ulcer/ bleed 6. condition involve increased tendency bleed 7. active know inflammatory bowel disease ( e.g . colitis ulcerosa , Crohn´s disease ) 8. history relevant CNS and/or psychiatric disorder and/or currently treat CNS and/or psychiatric disorder 9. know allergic reaction active ingredient use constituent pharmaceutical preparation 10. history hypersensitivity reaction ( e.g . bronchial spasm , asthma , rhinitis , urticaria , angioedema ) intake acetylsalicylic acid NSAIDs 11. subject severe allergy multiple drug allergy unless judge relevant clinical trial investigator 12. existing , history , bronchial asthma , chronic rhinitis allergic diseases unless judge relevant clinical trial investigator 13. subject hereditary problem galactose intolerance , lactase deficiency glucosegalactose malabsorption 14. systolic blood pressure &lt; 90 &gt; 145 mmHg 15. diastolic blood pressure &lt; 60 &gt; 90 mmHg 16. heart rate &lt; 50 bpm &gt; 90 bpm 17. laboratory value normal range unless deviation normal judge relevant clinical trial investigator except parameter ASAT , ALAT , bilirubin creatinine ( see exclusion criterion No . 18 ) 18. laboratory value : ASAT &gt; 20 % ULN , ALAT &gt; 10 % ULN , bilirubin &gt; 20 % ULN creatinine &gt; 9 μmol/l ULN 19. positive antiHIVtest ( positive verify western blot ) , HBsAGtest ( positive verify test HBcIgM ) antiHCVtest 20. acute chronic disease may interfere pharmacokinetics IMP 21. history current drug alcohol dependence 22. positive alcohol drug test screen examination 23. regular intake alcoholic food beverage ≥ 40 g pure ethanol male ≥ 20 g pure ethanol female per day 24. subject diet could affect pharmacokinetics active ingredient 25. regular intake caffeine contain food beverage ≥ 500 mg caffeine per day 26. blood donation blood loss 400 ml within last 2 month prior individual enrolment subject 27. administration investigational medicinal product last 2 month prior individual enrolment subject 28. regular treatment systemically available medication ( except hormonal contraceptive ) 29. subject , report frequent occurrence migraine attack 30. positive pregnancy test screen examination 31. pregnant lactate woman 32. female subject agree apply highly effective contraceptive method 33. subject suspect know follow instruction 34. subject unable understand write verbal instruction , particular regard risk inconvenience expose participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Ibuprofen</keyword>
</DOC>